For the first six months of 1996, the pharmaceutical market in Finlandgrew 9% (at wholesale price level) to a value of 2.5 billion markka ($541.8 million). This is a slight slow down on 1995, when overall sales increased 10% to 4.69 billion markka.
Prescription medicine sales were up 11%, compared with only 2% for over-the-counter medicines. The latter, according to the European Proprietary Medicines Manufacturers' Association, accounted for 838 million markka of 1995 sales. This is equal to the European average of around 18% of total pharmaceutical turnover.
The AESGP also notes that self-regulatory controls play a central part in the marketing of OTC products in Finland, alongside the Code for Marketing Medicinal Products, a revised version of which came into effect January 1, 1997. The biggest change in this concerns the organization of the Supervisory Commission for the Marketing of Medicinal Products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze